



STROKE

DEMENTIA

TBI

## New Canadian TBI-Guideline 1b recommendation for Cerebrolysin®

Cerebrolysin inclusion in **E**vidence-Based **R**eview of moderate to severe **A**cquired **B**rain **I**njury

**ERABI** EVIDENCE-BASED REVIEW  
of moderate to severe  
ACQUIRED BRAIN INJURY

- Cerebrolysin improves attention
- International recognition
- The only evidenced based agent in brain trauma


**Cerebrolysin®**

Reconnecting Neurons.  
Empowering for Life.

# Cerebrolysin – recommended agent for attention improvement after TBI

- Cerebrolysin is the **only evidence based pharmacological agent** in brain trauma recovery
- **Positive 1b evidence** in Canada
- Cerebrolysin **improves attentional function** following brain injury
- **International recognition** – Cerebrolysin recommended by the Canadian ERABI guidelines
- Cerebrolysin takes care of one of the main consequences of TBI – **attention and concentration deficits**

## Cerebrolysin – best ranked in guidelines for attention improvement



full guideline

**Titel:** Attention, Concentration & Information Processing Post Acquired Brain Injury  
"Modul 6 – Attention, Concentration & Information Processing"

**Website:** <https://erabi.ca/>

**Relevant clinical data:** Alvarez et al., 2003; Poon et al., 2020; Vester et al., 2021

Copyright © 2023 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorization Holder: EVER Neuro Pharma GmbH, A-4866 Unterach Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC-CCDS Version 2.0/03.06.2016)